Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus Dosage by CYP3A5 Genotype in Renal Transplant
NCT00935298Phase 4Completed
- Sponsor
- PLA Rocket Force Characteristic Medical Center
- Start
- Jul 2009
- Primary completion
- Dec 2010
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tacrolimus in kidney transplant rejection, sponsored by PLA Rocket Force Characteristic Medical Center. Started Jul 2009; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00935298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00935298.